Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
| Project Name | Modality | Therapeutic Area | Indications | Stage | Right Available |
| IL17A mAb | Monospecific antibody | Immunological disease | Psoriasis,Axial spondyloarthritis SpA | Phase III | Global (except China) |
Human IL-17A, premium grade (Cat. No. ILA-H5219) stimulates Human IL-17 RA/IL-17 RC (Luc) HEK293 Reporter Cell. The specific activity of Human IL-17A, premium grade is > 1.00ⅹ10^7 IU/mg, which is calibrated against human IL-17 WHO International Standard (NIBSC code: 01/420) (QC tested).
Human IL-17 RA Protein, Fc Tag (Cat. No. ILA-H525f) captured on Protein A Chip can bind Human IL-17A Protein, His Tag (Cat. No. ILA-H5243) with an affinity constant of 0.360 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Vunakizumab | SHR-1314 | Approved | Jiangsu Hengrui Medicine Co Ltd | 安达静 | Mainland China | Plaque psoriasis | Suzhou Suncadia Biopharmaceuticals Co Ltd | 2024-08-20 | Non-radiographic axial spondyloarthritis; Autoimmune Diseases; Spondylitis, Ankylosing; Spondylarthritis; Graves Ophthalmopathy; Lupus Nephritis; Psoriasis; Graves Disease; Arthritis, Psoriatic; Plaque psoriasis | Details |
| Ixekizumab | LY-2439821 | Approved | Eli Lilly And Company | 拓咨, Taltz | United States | Psoriasis | Eli Lilly And Company | 2016-03-22 | Diabetes Mellitus, Type 1; Non-radiographic axial spondyloarthritis; Pyoderma Gangrenosum; Depressive Disorder, Major; Spondylarthritis; Spondylitis, Ankylosing; Arthritis, Rheumatoid; Psoriasis; Lichen Planus; Arthritis, Psoriatic; Pemphigoid, Bullous; Pityriasis Rubra Pilaris; Plaque psoriasis | Details |
| Xeligekimab | GR-1501 | Approved | Chongqing Zhixiang Jintai Biopharmaceutical Co Ltd, Genrix (Shanghai) Biopharmaceutical Co Ltd | 金立希 | Mainland China | Plaque psoriasis | Chongqing Zhixiang Jintai Biopharmaceutical Co Ltd | 2024-08-20 | Non-radiographic axial spondyloarthritis; Spondylarthritis; Lupus Nephritis; Psoriasis; Plaque psoriasis | Details |
| Virulizin | Approved | Aptose | Virulizin, Virulizin-2 gamma | Mexico | Colorectal Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms; Uterine Cervical Neoplasms; Sarcoma, Kaposi; Melanoma; Carcinoma, Renal Cell | null | 1997-01-01 | Stomach Neoplasms; Carcinoma, Renal Cell; Pancreatic Neoplasms; Colorectal Neoplasms; Uterine Cervical Neoplasms; Sarcoma, Kaposi; Melanoma | Details | |
| Secukinumab | AIN-457; KB-03303A; NVP-AIN-457 | Approved | Novartis Pharma Ag | 可善挺, Scapho, Cosentyx | Japan | Psoriasis; Arthritis, Psoriatic | Novartis Pharma Ag | 2014-12-26 | Hidradenitis Suppurativa; Multiple Sclerosis; Ichthyosis, Lamellar; Tendinopathy; Psoriasis; Hyperkeratosis, Epidermolytic; Arthritis, Psoriatic; Tendon Injuries; Asthma; Lichen Planus; Graves Ophthalmopathy; Arthritis; Uveitis; Inflammation; Plaque psoriasis; Behcet Syndrome; Gastroenteritis; Dermatitis, Atopic; Crohn Disease; Ichthyosiform Erythroderma, Congenital; Spondylitis, Ankylosing; Necrobiosis Lipoidica; Multiple Sclerosis, Relapsing-Remitting; Diabetes Mellitus, Type 1; Giant Cell Arteritis; Pyoderma Gangrenosum; Lupus Erythematosus, Discoid; Alopecia Areata; Inflammatory Bowel Diseases; Metabolic Dysfunction-Associated Steatotic Liver Disease; Non-radiographic axial spondyloarthritis; Spondylarthritis; Arthritis, Rheumatoid; Rotator Cuff Injuries; Spondylarthropathies; Netherton Syndrome; Ichthyosis; Lupus Nephritis; Arthritis, Juvenile; Polymyalgia Rheumatica | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| QX002N | QX-002N | Phase 3 Clinical | Qyuns Therapeutics Co Ltd | Spondylitis, Ankylosing; Asthma | Details |
| Roconkibart | JS005 | Phase 3 Clinical | Shanghai Junshi Biosciences Co Ltd | Non-radiographic axial spondyloarthritis; Spondylarthritis; Spondylitis, Ankylosing; Psoriasis; Plaque psoriasis | Details |
| Izokibep | AFB-035; ABY-035; IMG-020; IMG020; ABY-035/AFO2 | Phase 3 Clinical | Affibody Ab | Spondylitis, Ankylosing; Psoriasis; Arthritis, Psoriatic; Hidradenitis Suppurativa; Uveitis; Plaque psoriasis | Details |
| Sonelokimab | ALX-0761; MSB-0010841; M-1095 | Phase 3 Clinical | Ablynx Nv | Psoriasis; Arthritis, Psoriatic; Hidradenitis Suppurativa | Details |
| Recombinant human IL-17A/F humanized antibody (Livzon Pharmaceutical Group) | LZM－012; LZM012; XKH004; XKH-004 | Phase 3 Clinical | Beijing Kanova Biomedical Technology Co Ltd, Livzon Pharmaceutical Group Inc | Spondylitis, Ankylosing; Psoriasis; Plaque psoriasis | Details |
| Secukinumab Biosimilar(Celltrion) | CT-P55 | Phase 3 Clinical | Celltrion Inc | Multiple Sclerosis; Plaque psoriasis | Details |
| Secukinumab Biosimilar(Mabtech) | CMAB-015; CMAB015 | Phase 3 Clinical | Taizhou Mabtech Pharmaceutical Co Ltd | Spondylitis, Ankylosing; Psoriasis; Plaque psoriasis | Details |
| DMT-310 | DMT-310 | Phase 3 Clinical | Dermata | Acne Vulgaris; Rosacea | Details |
| SIM-0335 | SIM-0335; SIM-335 | Phase 2 Clinical | BCY Pharm Co Ltd | Plaque psoriasis | Details |
| SCT-650C | SCT650C; SCT-650-C; SCT-650C | Phase 2 Clinical | SinoCelltech Ltd | Non-radiographic axial spondyloarthritis; Autoimmune Diseases; Spondylitis, Ankylosing; Arthritis, Rheumatoid; Spondylarthritis; Plaque psoriasis | Details |
| DC-853 | DC-853; LY4100511; LY-4100511 | Phase 2 Clinical | Dice Therapeutics Inc | Immune System Diseases; Plaque psoriasis | Details |
| Isomyosamine | MYMD-1 | Phase 2 Clinical | Mymd Pharmaceuticals Inc | Anxiety; Frailty; Hashimoto Disease; Depression; Coronavirus Disease 2019 (COVID-19); Arthritis, Rheumatoid; Healthy Aging; Inflammation; Sarcopenia | Details |
| ZL-1102 | ZL-1102; CB-001 | Phase 2 Clinical | Crescendo Biologics Ltd | Psoriasis; Plaque psoriasis | Details |
| CJM-112 | CJM-112 | Phase 1 Clinical | Novartis Pharma Ag | Acne Vulgaris; Triple Negative Breast Neoplasms; Multiple Myeloma; Multiple Sclerosis; Psoriasis; Colorectal Neoplasms; Asthma; Hidradenitis Suppurativa; Acneiform Eruptions; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Plaque psoriasis | Details |
| Tibulizumab | LY-3090106; LY3090106; ZB-106 | Phase 1 Clinical | Eli Lilly And Company | Sjogren's Syndrome; Arthritis, Rheumatoid; Sjogren-Larsson Syndrome | Details |
| CNTO-6785 | CNTO-6785; FTC-001 | Phase 1 Clinical | Morphosys Ag, Johnson & Johnson Innovative Medicine | Arthritis, Rheumatoid; Spondylitis, Ankylosing; Psoriasis; Arthritis, Psoriatic; Pulmonary Disease, Chronic Obstructive | Details |
| JNJ-61178104 | JNJ-61178104 | Phase 1 Clinical | Johnson & Johnson Innovative Medicine | Autoimmune Diseases | Details |
| Secukinumab biosimilar (BioRay Pharmaceutical) | BR-201 | Phase 1 Clinical | BioRay Pharmaceutical Co Ltd | Autoimmune Diseases; Spondylitis, Ankylosing; Psoriasis; Plaque psoriasis | Details |
| JNJ-63823539 | JNJ-63823539 | Phase 1 Clinical | Johnson & Johnson Innovative Medicine | Arthritis, Rheumatoid | Details |
| Secukinumab biosimilar (CSPC Pharmaceutical Group) | SYS6012; SYS-6012 | Phase 1 Clinical | CSPC Pharmaceutical Group Ltd | Plaque psoriasis | Details |
| Secukinumab biosimilar (Gan & Lee) | GLR1023; GLR-1023 | Phase 1 Clinical | Gan & Lee Pharmaceuticals | Plaque psoriasis | Details |
| anti-IL-17A humanized monoclonal antibody(Fontacea ) | Phase 1 Clinical | Shandong Fangtansi Biopharmaceutical Co Ltd | Plaque psoriasis | Details | |
| LEO-153339 | LEO-153339 | Phase 1 Clinical | Leo Pharma Inc | Details | |
| HY-1770 | HY-1770; HT-17; HT17; YF02; HT25; GH02; HY1770 | Phase 1 Clinical | Suzhou Pharmavan Co Ltd | Plaque psoriasis; Dermatitis, Atopic | Details |
| UCB-0159 | UCB-0159 | Phase 1 Clinical | Ucb Sa | Autoimmune Diseases | Details |
This web search service is supported by Google Inc.
A-Z
